Mark A Glickman - Net Worth and Insider Trading
Mark A Glickman Net Worth
The estimated net worth of Mark A Glickman is at least $1,423 dollars as of 2024-12-26. Mark A Glickman is the Co-CEO of TherapeuticsMD Inc and owns about 1,294 shares of TherapeuticsMD Inc (TXMD) stock worth over $1,423. Details can be seen in Mark A Glickman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark A Glickman has not made any transactions after 2022-12-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark A Glickman
Mark A Glickman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark A Glickman owns 4 companies in total, including Esperion Therapeutics Inc (ESPR) , Old API Wind-down Ltd (ARLZQ) , and TherapeuticsMD Inc (TXMD) among others .
Click here to see the complete history of Mark A Glickman’s form 4 insider trades.
Insider Ownership Summary of Mark A Glickman
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ESPR | Esperion Therapeutics Inc | 2018-12-20 | Chief Commercial Officer |
| ARLZQ | Old API Wind-down Ltd | 2018-03-19 | Chief Commercial Officer |
| TXMD | TherapeuticsMD Inc | 2022-12-06 | Chief Business Officer |
 | | 2023-05-11 | director |
Mark A Glickman Latest Holdings Summary
Mark A Glickman currently owns a total of 1 stock. Mark A Glickman owns 1,294 shares of TherapeuticsMD Inc (TXMD) as of December 6, 2022, with a value of $1,423.
Latest Holdings of Mark A Glickman
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TXMD | TherapeuticsMD Inc | 2022-12-06 | 1,294 | 1.10 | 1,423 |
Holding Weightings of Mark A Glickman
Mark A Glickman Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark A Glickman has made a total of 1 transactions in TherapeuticsMD Inc (TXMD) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in TherapeuticsMD Inc is the sale of 440 shares on December 6, 2022, which brought Mark A Glickman around $2,165.
Insider Trading History of Mark A Glickman
- 1
Mark A Glickman Trading Performance
Mark A Glickman Ownership Network
Mark A Glickman Owned Company Details
What does Esperion Therapeutics Inc do?
Who are the key executives at Esperion Therapeutics Inc?
Mark A Glickman is the Chief Commercial Officer of Esperion Therapeutics Inc. Other key executives at Esperion Therapeutics Inc include Chief Financial Officer Benjamin Halladay , Chief Operating Officer Sheldon L. Koenig , and Chief Commercial Officer Eric Warren .
Esperion Therapeutics Inc (ESPR) Insider Trades Summary
Over the past 18 months, Mark A Glickman made no insider transaction in Esperion Therapeutics Inc (ESPR). Other recent insider transactions involving Esperion Therapeutics Inc (ESPR) include a net sale of 9,288 shares made by Eric Warren , a net sale of 26,997 shares made by Sheldon L. Koenig , and a net sale of 4,202 shares made by Joanne M. Foody .
In summary, during the past 3 months, insiders sold 18,230 shares of Esperion Therapeutics Inc (ESPR) in total and bought 0 shares, with a net sale of 18,230 shares. During the past 18 months, 43,732 shares of Esperion Therapeutics Inc (ESPR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 43,732 shares.
Esperion Therapeutics Inc (ESPR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Esperion Therapeutics Inc Insider Transactions
Mark A Glickman Mailing Address
Above is the net worth, insider trading, and ownership report for Mark A Glickman. You might contact Mark A Glickman via mailing address: C/o Esperion Therapeutics, Inc., 3891 Ranchero Drive, Suite 150, Ann Arbor Mi 48108.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
